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osting by EAbstract Background: Statinsmay provide additional beneﬁts in patientswith cardiac failure due to
their pleiotropic effects besides their cholesterol-lowering actions. In this study, we aimed to evaluate
the impact of 12-week 40 mg atorvastatin therapy on the inﬂammatory markers, endothelium depen-
dent vasodilatation and the ventricular performance markers in patients with heart failure (HF).
Methods and results: Thirty chronic symptomatic heart failure patients, all with idiopathic dilated
cardiomyopathy (DCM) were included to this open label and prospective study. Thirty patients were
subdivided into two groups: group I – 15 patients whowere given 40 mg of atorvastatin and group II –
15 patients who were given a placebo. After a 12-week treatment with atorvastatin 40 mg/day; clinical
functional capacity, echocardiographic indices of cardiac performance and inﬂammatory markers
were evaluated. After the treatment, even though the left ventricular ejection fraction (LV EF) did
not improve signiﬁcantly in the group receiving statins (29.2 ± 6.18 to 29.73 ± 6.27 in the statin
group and 28.13 ± 5.81 to 27.93 ± 5.56 in the control group), both the 6 min walk test and Minne-
sota living with heart failure questionnaire improved signiﬁcantly (p= 0.000 and 0.022, respectively).
The ﬂow mediated dilatation in the brachial arteries also showed improvement in the statin receiving
group (8.9–13.8 in the statin group p= 0.0001, and 9.5–10.2 in the control group p= 0.055). In addi-
tion, the statin receiving group showed signiﬁcantly lower levels of highly sensitive C-reactive protein(S.S. El-Zahwy).
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16 O. Awwad et al.(hs-CRP) levels at follow up (4.6–1.93 in statin group p= 0.005, and 7.2–4.97 in the control group
p= 0.176).
Conclusion: Short term atorvastatin treatment improved functional capacity and the clinical symp-
toms inHFpatientswith idiopathic dilated cardiomyopathy. This positive effect of atorvastatinmight
be secondary to inﬂammatory modulation and improvement of endothelial function. Statins in HF
deserve special attention by means of further large-scale trials.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase
inhibitors, or statins are drugs that were originally designed
to lower high levels of plasma cholesterol in hyperlipidemic
patients, and were found to improve endothelial functions
and decrease plasma concentrations of tumor necrosis factor
(TNF) in patients with coronary artery disease and hyperlipid-
emia. Statins have also been shown to reduce morbidity and
mortality in those patients.1
However there is increasing evidence of beneﬁt in using
statins to treat patients with normal cholesterol level and
non-ischemic heart failure. In such patients statins treatment
improves endothelial functions and neurohormonal imbalance
as shown in the experimental and clinical studies.2
Statins may retard the progression of chronic heart failure,
not only through effects that may directly impact coronary
ischemia, namely restoration of endothelial function and pla-
que stabilization, but also by additional properties such as ef-
fects on myocardial function, down-regulation of AT-1
receptors, and inhibition of pro-inﬂammatory cytokines.3
As statins improve peripheral and coronary endothelial
functions through low density lipoproteins lowering and pleio-
tropic mechanisms, treatment with statins would improve
hemodynamic abnormalities in patients with cardiac failure
even in the absence of underlying coronary artery disease.4
Accordingly we were aiming to study the effects of short term
atorvastatin therapy on functional capacity, clinical symp-
toms, endothelial functions and cardiac function in patients
with normo-cholesterolemic idiopathic dilated cardiomyopa-
thy in a placebo-controlled study.
2. Patients and methods
The study was conducted on 30 patients presenting with
chronic symptomatic heart failure, diagnosed to have idio-
pathic dilated cardiomyopathy (DCM) who were recruited
from the Cardiology Department at the outpatient clinic at
the Ain Shams University Hospital during their follow up
visits. All patients were receiving standard anti-failure treat-
ment in the form of loop diuretics, B-blockers plus an
angiotensin converting enzyme inhibitor or angiotensin II
receptor blocker with or without digoxin and spironolactone
in unchanged dose for at least one month before the study.
The patients were divided into two groups: group I – 15
patients who were maintained on atorvastatin 40 mg for
3 months in addition to their full anti-failure treatment
and group II – 15 patients who were maintained on placebo
for the same period of three months besides their full anti-
failure treatment.Inclusion criteria were:
1. Non-ischemic heart failure, with an LV ejection fraction of
<40%.
2. Normal lipoprotein pattern.
3. Symptomatic heart failure (HF), New York Heart Associa-
tion (NYHA) functional class II or III.
4. Anti-failure drugs ﬁxed for 1 month before the study.
While exclusion criteria were:
1. Presence of ischemic heart disease.
2. Any renal, hepatic or pulmonary vascular dysfunction.
3. Valvular heart disease.
All patients were subjected to the following:
1. History taking.
2. Clinical examination.
3. Assessment of quality of life for all patients guided by
Minnesota living with a heart failure questionnaire
(MLHFQ).5:
This questionnaire was designed to measure the effects of
heart failure and treatments of heart failure on an individual
quality of life.6 It is also used to measure the effect of symp-
toms, functional limitations and psychological distress on an
individual’s quality of life. The MLHF questionnaire asks each
person to indicate using a six point, zero to ﬁve, Likert scale as
to how much each of the 21 facets prevented them from living
as they desired by marking either 0, 1, 2, 3, 4 or 5 to indicate
how much the selected symptom, functional limitation or psy-
chological distress affected the patient’s life during the past
month where zero (0) means not at all, one (1) means very little
and ﬁve (5) very much.
4. Assessment of highly sensitive C-reactive protein (hs-CRP)
as laboratory markers of endothelial functions.
Samples for hs-CRP were analyzed in the local laboratory.
Samples were analyzed within 24 h using the Synchron LX 20
system CRPH reagent (Beckman Coulter, High Wycombe,
UK) assay.7
5. The 6 min walk test (6MWT).
The 6MWT is a useful measure of functional capacity
targeted at people with mild or moderate impairment. It has
been widely used for measuring the response to therapeutic
interventions for pulmonary and cardiac diseases. The new
American Thoracic Society guidelines provide a standardized
Table 1 Demographic data distribution in both groups.
Age
Mean ± SD
Gender
Males Females
Study population Group I 50.600 ± 11.128 8 7
Group II 45.600 ± 7.726 8 7
T-test t 0.359 3.334
p-Value 0.722 (NS) 0.872 (NS)
Table 2 Risk factors distribution in both groups.
HTN DM Smoking
Group I 6 6 6
Group II 1 3 6
p-Value 0.000 0.292 (NS) 0.977 (NS)
Short term statin treatment in idiopathic dilated cardiomyopathy 17approach for performing the test. Absolute contraindications
for the 6MWT include the following: unstable angina during
the previous month and myocardial infarction during the
previous month. Relative contraindications include a resting
heart rate of more than 120, a systolic blood pressure of more
than 180 mm Hg, and a diastolic blood pressure of more than
100 mm Hg.8 The 6MWT was performed indoors, along a ﬂat,
straight, enclosed corridor with a hard surface that is seldom
raveled. If the weather was comfortable, the test may be
performed outdoors.
6. Brachial ultrasound.
Conduit artery function was assessed by brachial ultra-
sound based on the protocol described by Celermajer et al.9
The assessment adhered to guidelines published by the Interna-
tional Brachial Reactivity Task Force and used a fully digital-
ized ultrasound system (GE Medical Systems) with a high-
resolution, broad-spectrum transducer.10 The brachial artery
was imaged in the longitudinal plane during the baseline
resting phase, after 5 min of forearm ischemia to assess endo-
thelium-dependent ﬂow-mediated dilatation (FMD) and after
sublingual nitrates that were given to assess endothelium-inde-
pendent dilatation (EID).
7. Transthoracic echocardiography.
Transthoracic echocardiographic examinations were per-
formed using a General electric echocardiogram VIVID 5.
The examination was conducted with participants in the left
lateral position. M, mode echocardiographic variables were
measured according to the recommendations of the American
Society of Echocardiography.1,11 Left ventricular ejection
fraction was calculated.
2.1. Statistical analysis
All the data were gathered, tabulated, and statistically
analyzed on a PC computer using the commercially available
statistical software package SPSS 12. The following tests were
done:1. Mean standard deviation (SD).
2. T test and Wilcoxon signed-rank test for independent
samples.
3. Chi square test (v2).
4. ANOVA test.
Data are presented as mean ± SD with 95% CI. p< 0.05
was considered signiﬁcant.
3. Results
All patients were age and sex matched (Table 1). Risk factors
distribution are shown in (Table 2).
Use of statins in the current study was associated by
signiﬁcant improvement of the functional capacity as assessed
by 6MWT (p< 0.05) (Table 3), MLHF questionnaire
(p= 0.022) (Table 4) and NYHA functional class (Tables 5
and 6).
In statins-treated patients, there was a signiﬁcant reduction
of hs-CRP (p= 0.005) (Table 7) in addition to signiﬁcant
improvement of endothelial functions as assessed by improve-
ment of FMD measured by brachial ultrasound (Table 8).
However, use of statins was not associated with a statisti-
cally signiﬁcant improvement of LVEF as assessed by echocar-
diography (Fig. 1).
4. Discussion
The beneﬁts of statins in heart failure are supported by exper-
imental and clinical studies. Statins were originally designed to
lower plasma cholesterol. However, the idea that statins medi-
ate effects beyond cholesterol lowering, namely through the so-
called pleiotropic effects, is gaining increased strength.12
Furthermore, evidence in favor of the therapeutic beneﬁts
of statin treatment in patients with non-ischemic heart failure,
irrespective of serum cholesterol values or atherosclerotic dis-
ease, has been recently provided by several authors.13
We studied the effects of statins versus placebo in 30 pa-
tients suffering from dilated cardiomyopathy. This was done
through several parameters including assessment of the func-
tional capacity of the patients included in the study using
6MWT and MLHFQ scoring before and after the use of stat-
ins and placebo in both groups. Measurement of hs-CRP was
done for all patients included in the study as a marker of endo-
thelial functions and to detect any improvement of endothelial
inﬂammation found in patients with CHF.
Brachial ultrasound was done for the assessment of
improvement in the functions of the endothelial tissues
through measurement of FMD and EID before and after the
use of statins and placebo. Finally assessment of systolic func-
Table 3 6MWT in both groups.
6MWT Before After Paired T-test
Mean ± SD Mean ± SD t p-Value
Study population
Statins 287.271 ± 44.401 333.579 ± 36.361 7.579 0.000*
Placebo 274.040 ± 50.120 278.087 ± 52.443 1.600 0.132 (NS)
Table 4 The MLHFQ scoring in both groups.
MLHFQ scoring Before After Paired T-test
Mean ± SD Mean ± SD t p-Value
Study population
Statins 33.667 ± 8.964 31.267 ± 7.934 2.581 0.022*
Placebo 26.000 ± 6.568 26.133 ± 7.019 0.323 0.751 (NS)
Table 5 NYHA functional class before the onset of
treatment.
NYHA class Total
II III
Statins
N 7 8 15
% 46.67 53.33 100.00
Placebo
N 5 10 15
% 33.33 66.67 100.00
Chi-square
v2 3.467
p-Value 0.325
Table 6 NYHA functional class after administration of
atorvastatin.
NYHA class Total
I II III
Statins
N 2 11 2 15
% 13.33 73.33 13.33 100.00
Placebo
N 1 6 8 15
% 6.67 40.00 53.33 100.00
Chi-square
v2 16.059
p-Value 0.013
Table 7 Showing hs-CRP levels at baseline and after 3 months of
hs-CRP Before After
Mean ± SD Mean ± SD
Study population
Statins 4.600 ± 3.470 1.926 ± 0.7
Placebo 7.286 ± 5.841 4.974 ± 5.1
18 O. Awwad et al.tions in patients with DCM was done using transthoracic
echocardiography for measurement of LVEF before and after
the use of drugs.
As regards the functional capacity of the patients and use of
statins were associated with clinical improvements detected
ﬁrst by improvement in the meters walked in the 6MWT. In
contrast, patients on placebo showed no signiﬁcant change in
meters walked in the 6MWT before and after the use of pla-
cebo. Also as regards MLHFQ scoring, patients who took
statins for 3 months showed an improvement in the scoring
scale. Improvement in MLHFQ scoring of more than or equal
to 5 points was considered to be clinically meaningful and suf-
ﬁcient for majority of patients in one study to take a medica-
tion that had no side effect or costs.14 In our study more
than 50% of the patients who showed an improvement in
MLHFQ scoring after treatment with statins gave an improve-
ment of more than or equal ﬁve points. This was in contrast to
patients on placebo who showed no signiﬁcant change in
MLHFQ scoring after 3 months of treatment.
The results of the current study as regards the improvement
of 6MWT and MLHFQ scorings are concordant with those of
Strey et al.13 and in their study they demonstrate that the short
term statin treatment improves endothelial function and neu-
rohormonal imbalance in normo-cholesterolemic patients with
non-ischemic heart failure with the resultant improvement of
the clinical parameters of functional capacity of the patients
namely the 6MWT and MLHFQ. Also the results of the cur-
rent study are concordant with Laufs et al.14 who randomized
a small number of patients with non-ischemic dilated cardio-
myopathy (NYHA classes II–III) to statins or placebo for an
average treatment period of 20 weeks. They observed that sta-atorvastatin or with placebo.
Wilcoxon signed ranks test
Z p-Value
42 3.302 0.005*
09 1.263 0.176 (NS)
Table 8 Baseline FMD and EID in both groups and follow up FMD and EID after 3 months of treatment (statins or placebo) in both
groups.
Study population Before After Paired T-test
Mean ± SD Mean ± SD t p-Value
FMD
Statins 8.933 ± 3.474 13.800 ± 3.550 12.934 0.000*
Placebo 9.533 ± 4.868 10.200 ± 4.960 2.092 0.055 (NS)
EID
Statins 9.533 ± 3.543 9.600 ± 3.641 0.564 0.582 (NS)
Placebo 10.200 ± 4.739 10.267 ± 4.713 0.435 0.670 (NS)
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Figure 1 Base line LVEF and follow up after 3 months of
treatment (statins or placebo).
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and exercise capacity of the patients.
Assessment of the functional capacity of all patients included
in the study was also done using the New York Heart Associa-
tion functional class (NYHA). The current study showed a
signiﬁcant decrease in the NYHA functional class in the
statin-treated patients in both groups but not in patients taking
placebo. The results of the current study are concordant with
those ofWojnicz et al.15 and in their study they demonstrate that
the treatment with atorvastatin in addition to standard therapy
for heart failure may signiﬁcantly improve clinical outcomes
leading to a signiﬁcant improvement of NYHA functional class
in this cohort of patients. Also the results are concordant with
the results obtained by Node et al.16 who demonstrated that pa-
tients with symptomatic non-ischemic dilated cardiomyopathy
(NYHA classes II–III) who were randomized to statins for
14 weeks had an improvement in the NYHA functional class.
Inﬂammatory markers are increased in chronic heart failure
(CHF), including high-sensitivity C-reactive protein (hs-CRP),
which is produced in the liver in response to the cytokine inter-
leukin-6 (IL-6).
Highly sensitive CRP as a marker of endothelial functions
showed a signiﬁcant reduction in its serum level when mea-
sured after 3 months of taking atorvastatin 40 mg. Patients
on placebo showed no signiﬁcant change in the serum levels
of hs-CRP after 3 months of treatment. The results of the cur-
rent study are concordant with those of Sola et al.17 and in
their study they concluded that the use of atorvastatin in pa-
tients with non-ischemic heart failure improves the vascular
markers of inﬂammation including hs-CRP, interleukin-6(IL-6), and tumor necrosis factor-alpha receptor II (TNF-a
RII). Also a study by Tousoulis et al.18 gave similar results
where they examined the use of low dose atorvastatin on the
inﬂammatory markers and endothelial function in patients
with heart failure, resultant improvement of endothelial
function and signiﬁcant reduction of inﬂammatory markers
including hs-CRP. Another study by Horwich et al.19 also gave
rise to similar results regarding the improvement in the endo-
thelial function and reduction of inﬂammatory biomarkers
with statin therapy in patients with heart failure.
The results of the current study as regards the signiﬁcant
reduction of serum levels of hs-CRP were different from those
of Bleske et al.20 and in their study they found that the use of
statins in patients with non-ischemic cardiomyopathy was
associated by neutral effect on the inﬂammatory markers
including hs-CRP, tumor necrosis factor-alpha, intracellular
adhesion molecule-1, and circulating levels of vascular adhe-
sion molecule-1. The difference in the results of the current
study from this study may be due to relatively small popula-
tion study conducted by Bleske et al. where the effects of stat-
ins were studied on 15 patients with non-ischemic heart failure.
In the current study assessment of endothelial function was
also done using brachial ultrasound for measurement of FMD
and EID. FMD showed a signiﬁcant improvement after
3 months of atorvastatin 40 mg therapy, while patients on pla-
cebo showed no improvement in FMD after 3 months of treat-
ment. EID showed no signiﬁcant change either with statin
therapy or in those of placebo. The current study gave rise to re-
sults that are concordant with Strey et al.13 in a study that inves-
tigate the effect of short term statin therapy on impaired
endothelium-dependant vasodilatation typically occurring in
chronic heart failure (CHF). After 6 weeks of placebo and ator-
vastatin 40 mg in patientswith non-ischemicCHF theFMDwas
signiﬁcantly improved after using statins but not in the placebo
group whereas EID did not change in either group.
LVEF was measured according to the recommendations of
the American Society of Echocardiography1 where it showed
no signiﬁcant change either with placebo or with statin therapy
in patients with DCM. The current study was different from
Wojnicz et al.15 in their study who found that there is a signiﬁ-
cant improvement (an increase of>5%) in the absolute left ven-
tricular ejection fraction in patients with DCM after using
atorvastatin 40 mg for 6 months. Also the current study was dif-
ferent from a study by Yamada et al.21 and Liu et al.22 who both
found that there is a signiﬁcant increase in the LVEF in patients
with chronic heart failure after using statins for a period of
31 ± 14 months. The difference in the results of the current
study from these studies may be due to the relatively short dura-
tion of the study in comparison to the other studies.
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Use of statins in normo-cholestrolemic patients with non-
ischemic heart failure improves the functional capacity of such
patients. Statin treatment when added to the standard antifai-
lure measures in patients with CHF improves endothelial func-
tion and lowers serum levels of inﬂammatory biomarkers.
Recommendations
Further investigations and larger randomized studies should
be undertaken to either conﬁrm or exclude the beneﬁt of stat-
ins in patients with normal lipid proﬁle and non-ischemic heart
failure.
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